Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The liver and lovastatin.

Keith G Tolman1

  • 1University of Utah School of Medicine, Salt Lake City, Utah 84132, USA.

The American Journal of Cardiology
|June 14, 2002
PubMed
Summary

Statins, widely used cholesterol-lowering drugs, rarely cause liver damage. Postmarketing data shows liver toxicity is uncommon, suggesting current monitoring may not be necessary for all patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The safety of thiazolidinediones.

Expert opinion on drug safety·2011
Same author

Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.

Drug safety·2009
Same author

Treatment of non-alcoholic fatty liver disease.

Therapeutics and clinical risk management·2008
Same author

Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders.

The American journal of gastroenterology·2008
Same author

Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease.

Diabetes care·2007
Same author

Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers.

Clinical drug investigation·2006

Area of Science:

  • Pharmacology
  • Hepatology
  • Clinical Therapeutics

Background:

  • Statins are common cholesterol-lowering drugs with a history of reported liver enzyme elevations.
  • Premarketing studies indicated potential hepatotoxicity, leading to mandatory liver enzyme monitoring.
  • Postmarketing surveillance suggests hepatotoxicity from statins is rare.

Purpose of the Study:

  • To re-evaluate the risk of statin-induced hepatotoxicity.
  • To assess the effectiveness of current liver enzyme monitoring protocols.
  • To determine if monitoring is necessary given the rarity of severe liver injury.

Main Methods:

  • Review of postmarketing data for statin use, focusing on lovastatin.
  • Analysis of reported cases of elevated liver enzymes and acute liver failure (ALF).
  • Comparison of ALF rates with lovastatin to background rates.

Main Results:

  • Minor elevations in alanine aminotransferase (ALT) occur in 2.6-5.0% of patients, are dose-related, reversible, and linked to cholesterol lowering.
  • Acute liver failure (ALF) is rare with lovastatin (1/1.14 million patient-years), comparable to background rates.
  • Monitoring for hepatotoxicity has not effectively prevented serious liver disease and may lead to unnecessary treatment discontinuation.

Conclusions:

  • Hepatotoxicity from statins is rare, and routine monitoring may not be beneficial.
  • The predictive value of minor ALT elevations is poor, potentially leading to false positives.
  • Discontinuation of beneficial statin therapy due to monitoring can pose risks to patients.

Related Experiment Videos